Q1 Net Profit Jumps to ₹1.05 Cr vs Loss YoY; Revenue Up 216% YoY to ₹8.77 Cr
Auro Laboratories reported revenue from operations of ₹8.77 Cr (₹876.81 Lakhs) for Q1 ended June 30, 2026, marking a 216% YoY surge compared to ₹2.77 Cr in Q1 FY26, though down 10.8% QoQ from ₹9.83 Cr. Net profit stood at ₹1.05 Cr (₹104.56 Lakhs), turning around from a net loss of ₹0.11 Cr in the prior-year quarter and up 7.7% QoQ from ₹0.97 Cr in Q4 FY26. Diluted EPS improved to ₹1.68 compared to negative ₹0.17 in Q1 FY26 and ₹1.56 in Q4 FY26. Operating performance reflects sustained revenue momentum above recent run-rates, with profitability remaining resilient despite raw material costs of ₹4.13 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுAuro Laboratories reported strong Q1 results with ₹1.05 Cr PAT, reversing from a net loss in the prior-year period.
ஏன் இது முக்கியம்Demonstrates operational stabilization with quarterly top-line maintaining the improved ~₹9 Cr run-rate established over FY26, boosting full-year earnings visibility.
Revenue from Operations (Q1): ₹876.81 லட்சம்Net Profit (Q1): ₹104.56 லட்சம்EPS (Basic & Diluted): ₹1.68வரிக்கு முன் லாபம்: ₹113.05 லட்சம்Paid-up Equity Capital: ₹623.25 லட்சம்
📅 குறுகிய காலம்Positive earnings turnaround on a YoY basis should support sentiment around the stock after recent quarterly corrections.
📈 நீண்ட காலம்Given the company's debt-to-equity ratio of 1.37 and small revenue base (~₹31 Cr TTM), consistent quarterly execution and debt servicing will be key structural monitorables.
⚠ அபாய எச்சரிக்கைகள்
- High D/E leverage (1.37x debt to equity)
- Small operating scale with single-segment pharmaceutical exposure
👀 கவனிக்க வேண்டியவை
Track whether the company can sustain quarterly revenues in the ₹9-10 Cr band in upcoming quarters and monitor margin sustainability against raw material cost trends.
